Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
November 16, 2019 12:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Rapid resolution of both reported pain and inflammation as well as improvement in quality of life scores -- Tapering and discontinuation of corticosteroids without pericarditis recurrence - -...
Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
October 28, 2019 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 –– Operating plan funded into 2H 2021; no current plan to raise additional capital prior to...
Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019
August 19, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
August 12, 2019 16:02 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Rilonacept pivotal Phase 3 study dosing patients in the U.S., Australia, Israel and Italy; expect to present final Phase 2 data this year – – Mavrilimumab global Phase 2 study dosing patients in...
Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community
August 05, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research
May 16, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 16, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity
May 02, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– First patient dosed in Phase 2a trial of KPL-716 in prurigo nodularis– Upcoming presentations at SID, ISPOR and EULAR scientific conferences on KPL-716, rilonacept and mavrilimumab, respectively–...
Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session
March 18, 2019 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period- Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in...
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial
December 11, 2018 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Phase 2 enrollment completed; interim clinical data show reductions in both inflammation and reported pain after first dose and throughout treatment period - Pivotal Phase 3 clinical trial,...